Monash IVF Group Ltd (ASX: MVF) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Monash IVF Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $331.19 million
P/E Ratio 17.12
Dividend Yield 2.49%
Shares Outstanding 389.63 million
Earnings per share 0.049
Dividend per share 0.04
Year To Date Return 10.32%
Earnings Yield 5.84%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
09 Mar 2021 $0.0210 100.00% Interim 07 Apr 2021
05 Mar 2020 $0.0210 100.00% Interim 02 Oct 2020
05 Sep 2019 $0.0300 100.00% Final 11 Oct 2019
06 Sep 2018 $0.0260 100.00% Final 12 Oct 2018
08 Mar 2018 $0.0340 100.00% Interim 06 Apr 2018
06 Sep 2017 $0.0450 100.00% Final 13 Oct 2017
02 Mar 2017 $0.0430 100.00% Interim 07 Apr 2017
06 Sep 2016 $0.0450 100.00% Final 14 Oct 2016
08 Mar 2016 $0.0400 100.00% Interim 08 Apr 2016
09 Sep 2015 $0.0370 100.00% 15 Oct 2015
12 Mar 2015 $0.0325 100.00% 08 Apr 2015

MVF ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Monash IVF Group Ltd

Monash IVF Group Ltd is a specialist assisted reproductive services provider. The company offers specialist diagnostic obstetric and gynaecological ultrasound and fertility treatments. The company's operating segment includes Australia andInternational. It generates maximum revenue from the Australian segment. Australia segment is a provider of Assisted Reproductive Services, Ultrasound, and other related services. The International segment is a provider of Assisted Reproductive Services in Malaysia.

MVF Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Jun 2021 $0.85 $-0.02 -2.33% 387,955 $0.88 $0.88 $0.85
10 Jun 2021 $0.86 $0.01 1.17% 220,218 $0.86 $0.89 $0.86
09 Jun 2021 $0.86 $0.00 0.00% 259,431 $0.85 $0.87 $0.85
08 Jun 2021 $0.86 $-0.02 -2.29% 223,144 $0.87 $0.87 $0.85
07 Jun 2021 $0.88 $-0.01 -1.14% 568,386 $0.88 $0.90 $0.87
04 Jun 2021 $0.88 $0.01 1.14% 419,230 $0.88 $0.89 $0.87
03 Jun 2021 $0.88 $-0.01 -1.14% 486,346 $0.87 $0.89 $0.86
02 Jun 2021 $0.88 $0.02 2.33% 194,684 $0.84 $0.88 $0.84
01 Jun 2021 $0.86 $0.00 0.00% 525,936 $0.86 $0.87 $0.83
31 May 2021 $0.86 $0.02 2.38% 320,573 $0.84 $0.86 $0.84
28 May 2021 $0.84 $-0.04 -4.57% 407,987 $0.88 $0.88 $0.84
27 May 2021 $0.88 $-0.03 -3.31% 178,056 $0.89 $0.90 $0.87
26 May 2021 $0.91 $0.05 5.81% 1,463,655 $0.86 $0.93 $0.86
25 May 2021 $0.86 $0.01 1.17% 925,294 $0.84 $0.88 $0.83
24 May 2021 $0.86 $0.03 3.64% 909,140 $0.84 $0.86 $0.83
21 May 2021 $0.83 $-0.01 -1.20% 406,412 $0.84 $0.84 $0.82
20 May 2021 $0.84 $0.00 0.00% 124,643 $0.83 $0.84 $0.83
19 May 2021 $0.84 $-0.01 -1.18% 394,241 $0.85 $0.85 $0.82
18 May 2021 $0.85 $0.00 0.00% 219,829 $0.85 $0.85 $0.82
17 May 2021 $0.85 $-0.02 -2.33% 501,594 $0.86 $0.87 $0.84
14 May 2021 $0.86 $-0.01 -1.15% 133,413 $0.86 $0.87 $0.86

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Apr 2021 Catherine West Buy 33 $29,959
On-market trade.
26 Apr 2021 Catherine West Buy 3 $3,382
On-market trade.
26 Apr 2021 Neil Broekhuizen Buy 217 $192,494
On-market trade.
24 Mar 2021 Michael Knaap Transfer 150 $105,458
As advised by the company. Transfer of 150,655 Ordinary Shares by
Michael and Michelle Knaap to MKN
Family Holdings Pty Ltd as trustee for the Pakhill Superannuation Fund.
24 Mar 2021 Michael Knaap Transfer 150 $105,458
As advised by the company. Transfer of 150,655 Ordinary Shares by
Michael and Michelle Knaap to MKN
Family Holdings Pty Ltd as trustee for the Pakhill Superannuation Fund.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Zita Peach Non-Executive Director Oct 2016
Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for major industry players such as CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita's most recent executive position is Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Fresenius Kabi, a leading provider of pharmaceutical products and medical devices to hospitals. Previously, Ms Peach was Vice President, Business Development, for CSL Limited, a position she held for ten years. Zita is Chair of Pacific Smiles Group Limited. She is also a member of the Hudson Institute of Medical Research Board.
Mr Josef Jerzy Czyzewski Non-Executive Director Jun 2014
Mr Czyzewski has over 30 years of experience in senior finance positions and significant experience in the health industry. Josef has held the positions of CFO at Healthscope Limited, and more recently CFO/General Manager Strategy and Development at Spotless Group Limited following its takeover by private equity interests in 2012. Prior to that time, Josef held various senior finance positions with BHP Billiton including VP Finance and Corporate Treasurer. He is Chair of Risk Management Committee.
Mr Richard Hugh Davis Non-Executive ChairmanNon-Executive Director Jun 2014
Mr Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is Member of Risk Management Committee.
Mr Neil John Broekhuizen Non-Executive Director Jun 2014
Mr Broekhuizen is the Joint Chief Executive Officer of Ironbridge. Neil has over 30 years experience in the finance industry, including 27 years in private equity with Investcorp and Bridgepoint in Europe, and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. Neil is currently the Independent Non-executive Chairman of Bravura Solutions, having previously served as a director. He is Member of Risk Management Committee.
Mr Michael Damian Knaap Chief Executive OfficerManaging Director Sep 2015
Mr Knaap has more than 17 years experience in senior finance executive roles in the FMCG sector in both listed and unlisted organisations. Michael's role prior to joining Monash IVF Group was with Patties Foods Limited where he held a number of executive positions in 6 years, including the role of CFO and Company Secretary.
Dr Richard Charles Henshaw Executive Director Apr 2014
Dr Henshaw has practiced in the field of reproductive medicine since 1995. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
Ms Catherine Jane West Non-Executive Director Sep 2020
Ms West is an experienced ASX listed non-executive director and has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe. Her knowledge covers commercial arrangements, corporate transactions and joint ventures, intellectual property, regulatory policy, media and advertising, consumer issues, remuneration, risk management, corporate governance and compliance, together with providing consultancy to the healthcare sector and to media companies internationally. Catherine is a non-executive director of ASX listed Nine Entertainment where she is Chair of the People and Remuneration Committee and a member of the Audit and Risk Committee. She was previously on the board of Southern Phone, a regional telecommunications company, before its sale to AGL. She currently holds positions of Vice-President of the Sydney Breast Cancer Foundation at Chris O'Brien Lifehouse, director of the NIDA Foundation and a Governor of Wenona School.
Mr Malik Jainudeen Chief Financial OfficerCompany Secretary Apr 2019
-
Malik Jainudeen Chief Financial OfficerCompany Secretary
-
Hamish Hamilton Chief Operations Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 96,545,066 24.78%
Citicorp Nominees Pty Limited 55,976,455 14.37%
HSBC Custody Nominees (Australia) Limited 36,242,265 9.30%
National Nominees Limited 32,957,311 8.46%
Argo Investment Limited 19,982,646 5.13%
BNP Paribas Nominees Pty Ltd 12,793,956 3.28%
Jangho Health Care Australia Pty Ltd 12,022,159 3.08%
XLY Holding Pty Ltd 4,901,414 1.26%
Citicorp Nominees Pty Limited i 3,686,700 0.95%
BNP Paribas Noms Pty Ltd 2,744,622 0.70%
Neweconomy COM AU Nominees 2,606,362 0.67%
Pacific Custodians Pty Limited 2,474,369 0.64%
Ippoliti Pty Ltd 2,011,336 0.52%
Vollenhoven Investments Pty Ltd 1,739,787 0.45%
Mr Prashant Nadkarni 1,461,484 0.38%
Dr Robert Ian McLachlan & Mrs Edwina Margaret McLachlan 1,385,944 0.36%
Payne Media Pty Ltd 1,300,850 0.33%
Ong Administration Pty Ltd 1,201,906 0.31%
Merrill Lynch 1,192,203 0.31%
Dalyne Pty Ltd 1,170,000 0.30%

Profile

since

Note